AU2024259627A1 - Methods of treating hepatic-only metastatic uveal melanoma - Google Patents
Methods of treating hepatic-only metastatic uveal melanomaInfo
- Publication number
- AU2024259627A1 AU2024259627A1 AU2024259627A AU2024259627A AU2024259627A1 AU 2024259627 A1 AU2024259627 A1 AU 2024259627A1 AU 2024259627 A AU2024259627 A AU 2024259627A AU 2024259627 A AU2024259627 A AU 2024259627A AU 2024259627 A1 AU2024259627 A1 AU 2024259627A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- dose
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363497590P | 2023-04-21 | 2023-04-21 | |
| US63/497,590 | 2023-04-21 | ||
| PCT/US2024/025461 WO2024220839A1 (en) | 2023-04-21 | 2024-04-19 | Methods of treating hepatic-only metastatic uveal melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2024259627A1 true AU2024259627A1 (en) | 2025-11-06 |
Family
ID=93153246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024259627A Pending AU2024259627A1 (en) | 2023-04-21 | 2024-04-19 | Methods of treating hepatic-only metastatic uveal melanoma |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4698282A1 (he) |
| KR (1) | KR20260005936A (he) |
| AU (1) | AU2024259627A1 (he) |
| IL (1) | IL324041A (he) |
| MX (1) | MX2025012553A (he) |
| WO (1) | WO2024220839A1 (he) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019060781A1 (en) * | 2017-09-22 | 2019-03-28 | Washington University | TARGETED PHARMACOLOGICAL THERAPEUTIC AGENTS IN UREAL MELANOMA |
| US11679113B2 (en) * | 2019-04-11 | 2023-06-20 | The Regents Of The University Of California | Anticancer treatment for uveal melanoma |
| US20230152322A1 (en) * | 2020-01-31 | 2023-05-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and treating uveal melanoma |
| WO2022055893A1 (en) * | 2020-09-08 | 2022-03-17 | Ideaya Biosciences Inc. | Pharmaceutical combination and tumor treatment |
-
2024
- 2024-04-19 KR KR1020257038639A patent/KR20260005936A/ko active Pending
- 2024-04-19 WO PCT/US2024/025461 patent/WO2024220839A1/en not_active Ceased
- 2024-04-19 AU AU2024259627A patent/AU2024259627A1/en active Pending
- 2024-04-19 EP EP24793593.5A patent/EP4698282A1/en active Pending
-
2025
- 2025-10-19 IL IL324041A patent/IL324041A/he unknown
- 2025-10-21 MX MX2025012553A patent/MX2025012553A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4698282A1 (en) | 2026-02-25 |
| MX2025012553A (es) | 2026-01-07 |
| WO2024220839A1 (en) | 2024-10-24 |
| KR20260005936A (ko) | 2026-01-12 |
| IL324041A (he) | 2025-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12427142B2 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid | |
| US20250090514A1 (en) | Method of treating cancer | |
| US20240207257A1 (en) | Combination therapy comprising a pkc inhibitor and a mek inhibitor | |
| TW202133857A (zh) | 用於乳癌治療之組合療法 | |
| EP3880207B1 (en) | Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof | |
| US20230040125A1 (en) | Targeting the intrinsic apoptotic machinery in glioblastoma | |
| WO2024220839A1 (en) | Methods of treating hepatic-only metastatic uveal melanoma | |
| EP4665325A1 (en) | Compositions and methods of using eflornithine | |
| US20240335440A1 (en) | Combination therapy comprising a pkc inhibitor and a c-met inhibitor | |
| WO2023175477A1 (en) | Treatment of breast cancer with amcenestrant | |
| KR20230044452A (ko) | 암을 치료하기 위한 bcl-2 억제제 및 저메틸화제의 조합물, 이의 용도 및 약학적 조성물 | |
| EP2968289A1 (en) | 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide for the treatment of hodgkin's lymphoma | |
| TW202029961A (zh) | Ar拮抗劑聯合parp抑制劑在製備治療前列腺癌的藥物中的用途 | |
| EP4085908A1 (en) | Pharmaceutical combination for treating tumors and application thereof | |
| WO2024044775A1 (en) | Methods of treating uveal melanoma | |
| US20260083731A1 (en) | Methods of treating uveal melanoma with a pkc inhibitor | |
| EP3265075B1 (en) | Roneparstat combined therapy of multiple myeloma | |
| CA3227813A1 (en) | Pharmaceutical composition for treating solid tumors | |
| HK40110657A (zh) | 用於治疗癌症的cdk4抑制剂 |